Daiichi Sankyo Forecasts Fall for Fiscal 2008 Due To Overseas Investments, R&D Growth
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Profits for fiscal 2007 were lower than expected and earnings are to decline for fiscal 2008 "under the challenging environment such as the National Health Insurance drug price revisions and the stronger yen," said Takashi Shoda, president and CEO of Daiichi Sankyo at its headquarters in Tokyo, May 14. Shoda also cited the company's heavy investment in overseas facilities and its R&D growth as factors for the negative forecast
You may also be interested in...
Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps
TOKYO - Daiichi Sankyo's German subsidiary reached an agreement to acquire approximately 130 primary-care medical representatives now working for Merck Serono in Germany as part of the Japanese company's European business expansion, a Daiichi Sangyo spokesman
Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps
TOKYO - Daiichi Sankyo's German subsidiary reached an agreement to acquire approximately 130 primary-care medical representatives now working for Merck Serono in Germany as part of the Japanese company's European business expansion, a Daiichi Sangyo spokesman
First Biosimilar Reviews Raise Questions About Differences In Asia
Regulators are beginning to decide on the acceptability of imitation biotech products, despite a continuing inability to fully ascertain how they differ from the brand products, or what the perceived differences actually mean